Without the ability to gather for events and meetings, the DeviceTalks team launched the DeviceTalks Weekly Podcast to keep our medtech community talking. Over the span of 9 months and 39 episodes, we interviewed dozens of medtech leaders from startups to multinational corporations to hear how they’re managing through the challenges of 2020. Our episodes […]
Thrive Earlier Detection Corp.
Stocks in the medtech industry hit a wall two weeks ago, and it’s been a quick drop for them ever since. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 91.01 (Oct. 30), marking a 6.4% drop from the 97.02 points registered at the end […]
Exact Sciences (NSDQ:EXAS) announced today that it is acquiring cancer detection tech developer Thrive Earlier Detection for $2.15 billion. Under the agreement, Thrive will receive the total consideration of up to $2.15 billion, which includes $1.7 billion payable at closing, comprised of 65% of Exact Sciences common stock and 35% in cash, according to a […]
In this week’s DeviceTalks Weekly Podcast, Karen Long, managing director at KCK Group, says startups looking for funding have an opportunity to catch the eye and ear of investors. KCK, an active medtech investor, has been involved in two sizable investments this summer including Aerin Medical and NeuroPace. Both were portfolio companies, but Long says […]
In this week’s podcast, two executives from Thrive Earlier Detection explain how the “turbo-charged” diagnostics company intends to upend how, when and where cancer is diagnosed. Dr. Isaac Kinde, co-founder and head of research and innovation, walks us through the company’s CancerSEEK test and how the company is marrying new technology with an innovative clinical […]
Investors once again lined up behind Thrive Earlier Detection and its potentially revolutionary cancer diagnostic The one-year-old start raised a $257 million Series B round from a syndicate of venture and crossover investors, including round leaders Casdin Capital and Section 32 and new investors Bain Capital Life Sciences, Brown Advisory, Driehaus Capital Management, Intermountain Ventures, […]